Valirx (VAL)


Latest News

ValiRx welcomes positive clinical results

ValiRx has provided an update on the clinical progress of an anti-cancer compound developed by ValiSeek, a joint venture...

ValiSeek Clinical Update (VAL401)

RNS Number: 9423B ValiRx PLC 16 January 2018 VALIRX PLC ("ValiRx", the "Company" or the "Group") VALISEEK CLINICAL UPDATE (VAL401) "Positive Impact of Patient Quality of Life and Immune Competency in VAL401 Phase II Clinical Trial" London, UK ., 16 January 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased...

ValiRx - ValiSeek Clinical Update, VAL401

ValiRx gets patent approval in the US

ValiRx, the clinical stage biotechnology company, has received patent approval in the US for its lead therapeutic compoun...

All News

16-01-18ValiRx welcomes positive clinical resultsStockMarketWire
16-01-18ValiSeek Clinical Update (VAL401)RNS
16-01-18ValiRx - ValiSeek Clinical Update, VAL401BRR Media
11-01-18ValiRx gets patent approval in the USStockMarketWire
11-01-18US Patent Notice of Allowance for Compound VAL201RNS
11-01-18ValiRx - US Patent Grant for VAL201BRR Media
04-01-18Holding(s) in CompanyRNS
03-01-18Exercise of Warrants and Issue of EquityRNS
27-12-17Final Loan Note Conversion and Issue of EquityRNS
22-12-17Issue of EquityRNS
21-12-17Result of General MeetingRNS
20-12-17Warrant ExerciseRNS
20-12-17Warrant ExerciseRNS
18-12-17Warrant ExerciseRNS
18-12-17re: VAL201 Clinical TrialsRNS
18-12-17Valirx - VAL201 Clinical TrialsBRR Media
15-12-17Exercise of Warrants and Issue of EquityRNS
12-12-17ValiRx releases encouraging test resultsStockMarketWire
12-12-17ValiSeek Clinical Development UpdateRNS
12-12-17ValiRx - ValiSeek Clinical Development UpdateBRR Media
11-12-17Loan Note Conversion and Issue of EquityRNS
06-12-17Shareholder Circular and Notice of General MeetingRNS
30-11-17Issue of EquityRNS
20-11-17Holding(s) in CompanyRNS
15-11-17Yorkville CLN ConversionRNS
11-10-17ValiRx obtains new US patent allowanceStockMarketWire
11-10-17Notification of US Patent AllowanceRNS
05-10-17Holding(s) in CompanyRNS
02-10-17Total Voting RightsRNS
28-09-17ValiRx cancer treatment JV progressing wellStockMarketWire
28-09-17ValiSeek Clinical Development UpdateRNS
28-09-17ValiRx - Valiseek Clinical Development UpdateBRR Media
27-09-17Holding(s) in CompanyRNS
26-09-17ValiRx interim loss narrowsStockMarketWire
26-09-17Half-year ReportRNS
26-09-17ValiRx - Half-year Report 2017BRR Media
20-09-17VAL201 updateRNS
19-09-17Issue of EquityRNS
13-09-17Hardman Research: GeneICE and VAL101 progressRNS
07-09-17ValiRx reports good progress in developing GeneICE technology platformStockMarketWire

RSS feeds

  • Editorial news feed for LSE:VAL Editorial
  • Regulatory news feed for LSE:VAL Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account